Participant’s characteristics
| Characteristics (no. of respondents) | Respondents (%) |
| Age, years (n=247) | |
| Under 30 | 11 (4.5) |
| 30–40 | 104 (42.1) |
| 41–50 | 64 (25.9) |
| 51–60 | 50 (20.2) |
| Over 60 | 18 (7.3) |
| Gender (n=246) | |
| Female | 158 (64.2) |
| Male | 88 (35.8) |
| Country* (n=245) | |
| India | 30 (12.2) |
| Brazil | 26 (10.6) |
| USA | 23 (9.4) |
| Canada | 20 (8.2) |
| Mexico | 14 (5.7) |
| Australia | 13 (5.3) |
| UK | 12 (4.9) |
| Chile | 11 (4.5) |
| Italy | 8 (3.3) |
| Portugal | 7 (2.9) |
| Belgium | 7 (2.9) |
| Others† | 74 (30.2) |
| Consider themselves to be from minority racial/ethnic group (n=245) | |
| Yes | 30 (12.2) |
| No | 215 (87.8) |
| Current clinical role (n=245) | |
| Resident | 6 (2.4) |
| Primary care practitioner, pediatrician, family doctor,or internal medicine doctor | 11 (4.5) |
| Pediatric endocrinology fellow | 18 (7.3) |
| Pediatric endocrinologist/diabetologist | 154 (62.9) |
| Adult endocrinology fellow | 1 (0.4) |
| Adult endocrinologist/diabetologist | 24 (9.8) |
| Nurse practitioner/registered nurse | 24 (9.8) |
| Other (registered nutritionist, dietitian, nutritionist, diabetes educator, mental health professional) | 13 (5.3) |
| Years of practice (n=246) | |
| Less than 3 | 42 (17.1) |
| 3–5 | 37 (15) |
| 5–10 | 46 (18.7) |
| More than 10 | 121 (49.2) |
| Main practice setting (n=245) | |
| Private hospital/outpatient clinic | 56 (22.9) |
| Public or government hospital/outpatient clinic | 73 (29.8) |
| University or academic hospital/outpatient clinic | 104 (42.5) |
| Primary care center | 4 (1.6) |
| General practitioner office | 2 (0.8) |
| Other (diabetes association) | 6 (2.5) |
| Access to an endocrinologist/diabetologist as a consultant (n=247) | |
| Yes | 56 (22.7) |
| No | 3 (1.2) |
| She/he is an endocrinologist/diabetologist | 188 (76.1) |
| Number of patients with T1D followed (n=247) | |
| Less than 100 | 71 (29.1) |
| 100–200 | 42 (16.9) |
| 201–500 | 59 (23.8) |
| More than 500 | 75 (30.2) |
| Provision of universal healthcare insurance/coverage for the use of insulin pump and/or CGM systems in your country (n=247) | |
| Yes | 65 (26.3) |
| No | 112 (45.3) |
| Partially | 70 (28.3) |
| Coverage/reimbursement of private insurance companies for insulin pump and/or CGM systems in your country (n=246) | |
| Yes | 57 (23.2) |
| No | 132 (53.7) |
| Partially | 59 (24) |
| Member of the International Society for Pediatric and Adolescent Diabetes (n=247) | |
| Yes | 173 (70) |
| No | 74 (30) |
*Top 11 country.
†Countries with response: Argentina, Bangladesh, Bulgaria, Denmark, Ecuador, Egypt, Finland, Germany, Greece, Haiti, Indonesia, Ireland, Israel, Japan, Liberia, Luxembourg, Malaysia, Malta, Mauritius, Morocco, Myanmar, Netherlands, Norway, Pakistan, Paraguay, Peru, Poland, Republic of Korea, Romania, Saudi Arabia, Serbia, Slovenia, South Africa, Spain, Sweden, Thailand, Turkey and Uruguay.
CGM, continuous glucose monitoring; T1D, type 1 diabetes.